<DOC>
	<DOCNO>NCT00754845</DOCNO>
	<brief_summary>RATIONALE : Estrogen cause growth breast cancer cell . Hormone therapy use letrozole may fight breast cancer lower amount estrogen body make . It yet know whether letrozole effective placebo treat woman breast cancer already receive 5 year aromatase inhibitor therapy . PURPOSE : This randomized phase III trial study letrozole see well work compare placebo treat woman primary breast cancer receive 5 year aromatase inhibitor therapy .</brief_summary>
	<brief_title>Letrozole Treating Women With Primary Breast Cancer Who Have Received 5 Years Aromatase Inhibitor Therapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - To compare disease-free survival woman primary breast cancer treat letrozole v placebo complete approximately 5 year ( i.e. , 4½ - 6 year ) aromatase inhibitor therapy ( e.g. , letrozole , anastrozole , exemestane ) . Secondary - To compare effect drug overall ( cause specific ) mortality patient . - To compare incidence contralateral breast cancer patient treat drug . - To evaluate long-term clinical laboratory safety aromatase inhibitor therapy , particularly cardiovascular morbidity mortality ( e.g. , significant coronary artery disease , include myocardial infarction angina require percutaneous transluminal coronary angioplasty coronary artery bypass graft , fatal nonfatal stroke , vascular death ) ; incidence bone fracture ( particular emphasis hip wrist fracture indicator osteoporosis ) ; change bone density ; common toxicity . - To compare overall quality life ( QOL ) menopausal-specific QOL patient treat drug . OUTLINE : This multicenter study . Patients stratify accord lymph node status diagnosis ( negative v positive v unknown ) , prior adjuvant chemotherapy ( yes v ) , interval last dose aromatase inhibitor therapy study randomization ( &lt; 6 month vs 6 month 2 year ) , duration prior tamoxifen citrate use ( 0 v &lt; 2 year vs 2 - 4½ year vs &gt; 4½ year ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral letrozole daily 5 year absence unacceptable toxicity , disease recurrence , development second malignancy . - Arm II : Patients receive oral placebo daily 5 year absence unacceptable toxicity , disease recurrence , development second malignancy . Patients undergo bone mineral density measurement DEXA scan baseline ( do within 12 month study entry ) , 24 48 month study therapy , completion study therapy . Some patient also complete quality-of-life questionnaire baseline 12 , 24 , 36 , 48 , 60 month . After completion study therapy , patient follow annually .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Previously diagnose primary breast cancer Must receive 4½ 6 year aromatase inhibitor therapy ( e.g. , letrozole , anastrozole , exemestane ) , either initial therapy prior tamoxifen citrate , include treatment receive part clinical trial CANNCICMA17 Completed aromatase inhibitor therapy ≤ 2 year ago No metastatic recurrent disease , contralateral breast cancer , ductal carcinoma situ either breast , determine follow : Clinical examination breast area , axilla , neck within past 60 day Mammogram within past 12 months* Chest xray within past 60 day Bone scan , alkaline phosphatase &gt; 2 time normal and/or symptom metastatic disease AND confirmatory xray , bone scan result questionable , within past 60 day Abdominal ultrasound , liver scan , CT scan abdomen within past 60 day , ALT , AST , alkaline phosphatase &gt; 2 time normal NOTE : *A baseline mammogram require patient undergone bilateral complete mastectomy Hormonereceptor status : Estrogen receptor positive ( ER+ ) and/or progesterone receptor positive ( PR+ ) primary tumor time diagnosis , define tumor receptor content &gt; 10 fmol/mg protein receptor positive immunocytochemical assay ( patient previously enrol clinical trial CANNCICMA17 ) ER+ and/or PR+ primary tumor OR hormone receptor status primary tumor unknown ( patient previously enrol clinical trial CANNCICMA17 ) PATIENT CHARACTERISTICS : Menopausal status specify ECOG performance status 02 Life expectancy ≥ 5 year WBC &gt; 3.0 x 10^9/L OR granulocyte count ( polymorphs + band ) ≥ 1.5 time 10^9/L Platelet count &gt; 100 x 10^9/L AST and/or ALT &lt; 2 time upper limit normal ( ULN ) * Alkaline phosphatase &lt; 2 time ULN* Able ( i.e . sufficiently fluent ) willing complete qualityoflife questionnaires either English French ( NCIC CTG participate center ) Inability complete questionnaire due illiteracy English French , loss sight , equivalent reason allow Accessible treatment followup No prior concurrent malignancy except adequately treat , superficial squamous cell basal cell skin cancer , carcinoma situ cervix , cancer treat &gt; 5 year ago presume cured NOTE : *Elevated level allow provide imaging examination rule metastatic disease PRIOR CONCURRENT THERAPY : See Disease Characteristics No concurrent selective estrogen receptor modulator ( e.g. , raloxifene , idoxifene ) No concurrent anticancer therapy</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>